| trastuzumab vedotin (MRG002) / Lepu Med |
MRG002-006, NCT04839510: A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer |
|
|
| Recruiting | 2 | 58 | RoW | MRG002 | Shanghai Miracogen Inc. | Locally Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma | 06/22 | 09/22 | | |
NCT04837508: A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer |
|
|
| Recruiting | 2 | 86 | RoW | MRG002 | Shanghai Miracogen Inc. | Advanced or Metastatic Biliary Tract Cancer | 12/22 | 08/23 | | |
NCT05263869: A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients |
|
|
| Recruiting | 2 | 99 | RoW | MRG002 | Shanghai Miracogen Inc. | Breast Cancer With Liver Metastases | 12/22 | 10/23 | | |
NCT04742153: A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC) |
|
|
| Recruiting | 2 | 66 | RoW | MRG002 | Shanghai Miracogen Inc. | Advanced or Metastatic Breast Cancer | 02/23 | 02/23 | | |
NCT05141786: A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC). |
|
|
| Not yet recruiting | 2 | 100 | RoW | MRG002 | Shanghai Miracogen Inc. | Non-small- Cell Lung Cancer (NSCLC) | 12/23 | 12/23 | | |
NCT05141747: A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer. |
|
|
| Recruiting | 2 | 60 | RoW | MRG002 | Shanghai Miracogen Inc. | Locally Advanced Gastric Cancer, Metastatic HER2 Positive Gastroesophageal Junction Cancer | 12/23 | 12/23 | | |
NCT04492488: A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer |
|
|
| Recruiting | 1/2 | 129 | US | MRG002 | Shanghai Miracogen Inc. | Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Cancer | 12/22 | 08/23 | | |
NCT05338957: A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. |
|
|
| Recruiting | 1/2 | 30 | RoW | MRG002+HX008 | Shanghai Miracogen Inc. | Advanced Malignant Solid Tumors | 06/24 | 12/24 | | |
